|
Checkmate 577:Health-related quality of life (HRQoL) in a randomized, double-blind phase III study of nivolumab (NIVO) versus placebo (PBO) as adjuvant treatment in patients (pts) with resected esophageal or gastroesophageal junction cancer (EC/GEJC). |
|
|
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; Biocartis; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; GlaxoSmithKline; Halozyme; Incyte; Lilly; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; SERVIER; Sirtex Medical; Taiho Pharmaceutical |
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Novartis (Inst); Roche (Inst); SERVIER (Inst) |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb |
Research Funding - Abbvie (Inst); AstraZeneca; Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Esperas Pharma; Merck; Merus (Inst); Roche/Genentech (Inst); Tesaro |
Travel, Accommodations, Expenses - Agios; Bristol-Myers Squibb; Roche |
|
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; Medscape; Merck; Novartis; Pieris Pharmaceuticals; Takeda |
Research Funding - Bristol-Myers Squibb (Inst); Lilly (Inst) |
|
|
Honoraria - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Lilly/ImClone; Merck Serono; MSD Oncology; Roche/Genentech; Servier; Taiho Pharmaceutical |
Consulting or Advisory Role - Amgen; Bayer; Lilly; Merck Serono; MSD; Nordic Group; Pfizer; Roche; SERVIER; Taiho Pharmaceutical; Yakult Pharmaceutical |
Research Funding - Amgen (Inst); AstraZeneca (Inst); Jennerex (Inst); Leap Therapeutics (Inst); Merck Serono (Inst); MSD (Inst) |
Travel, Accommodations, Expenses - Amgen; ASCO; Bayer; ESMO; German Cancer Society; Merck Serono; MSD; Roche |
|
|
Honoraria - Bristol-Myers Squibb; Roche |
Research Funding - Bristol Myers Squibb Foundation; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Zymeworks (Inst) |
Research Funding - Bristol-Myers Squibb; Zymeworks |
|
|
No Relationships to Disclose |
|
|
|
|
|
Employment - mployee of Adelphi Values, a consulting firm who has received payment from BMS for statistical data analysis in BMS' trials |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
|
|
|
|
|
|
|
|
No Relationships to Disclose |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
|
|
Honoraria - Acrotech Biopharma; Aduro Biotech; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; DAVA Pharmaceuticals; Lilly; Merck; zymeworks |
Consulting or Advisory Role - American Cancer Society; BeiGene; Bristol-Myers Squibb; Insys Therapeutics; Merck; Vaccinogen |
Research Funding - Amgen; Bristol-Myers Squibb; Daiichi Sankyo; Delta-Fly Pharma; Gilead Sciences; Lilly/ImClone; Merck; Novartis; ProLynx; Roche/Genentech; Taiho Pharmaceutical; Takeda; Zymeworks |
Patents, Royalties, Other Intellectual Property - I have research funding from: Genentech, Roche, BMS, Taiho, MedImmune, Merck, Amgen, Lilly |